PMEL and neoplasm: One day after the end of the treatment, we sorted the three main migratory DC subsets from the tumor-draining LNs (see online supplemental figure S4C for sorting strategy) and tested them for their ability to cross-present tumor-derived antigen to gp100-specific TCR-transgenic CD8+ T cells.23 The in vitro T cell proliferation confirmed that cDC1 cross-present tumor antigens and induce proliferation of gp100-specific CD8+ T cells.